Welcome!

Microsoft Cloud Authors: Elizabeth White, Mihai Corbuleac, Pat Romanski, David Bermingham, Steven Mandel

News Feed Item

Skystar Bio-Pharmaceutical Announces Results for Third Quarter Fiscal Year 2012

Veterinary Medication Facility Resumes Production and Distribution; Veterinary Vaccine Facility Receives Initial GMP Certification

XI'AN, CHINA -- (Marketwire) -- 11/15/12 -- Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI) ("Skystar" or the "Company"), a China-based manufacturer and distributor of veterinary medicines, vaccines, micro-organisms and feed additives, today reported unaudited third quarter fiscal year 2012 earnings, for the period ended September 30, 2012.

Third Quarter 2012 Highlights

  • Revenue decrease 57% YoY to $8.9 million
    • Veterinary vaccines totaled $1.0 million, up 19% YoY
    • Veterinary medicines totaled $1.8 million, down 86% YoY
    • Feed additives totaled $1.2 million, up 13% YoY
    • Probiotics products totaled $4.9 million, down 18% YoY
  • Gross margin of 59% for the third quarter of fiscal 2011 as compared to 52% in the year ago period
  • GAAP net income declined 65% to $2.7 million or $0.36 per fully diluted share, compared with net income of $7.7 million or $1.08 per fully diluted share in the year ago period
  • Fiscal 2012 top line revenue guidance range revised from $33 million to $38 million reflecting inactivity of the veterinary medications facility due to timing of its GMP re-certification process.

Nine Month 2012 Highlights

  • Net revenue declined 31% YoY to $25.7 million
  • Gross profit of $14.7 million for the nine months of fiscal 2012 as compared to $18.9 million in the year ago period
  • GAAP net income $6.3 million, compared with GAAP net income of $11.2 million in the year ago period

Mr. Weibing Lu, Skystar Bio-Pharmaceutical's Chairman and Chief Executive Officer, commented, "Skystar has made significant strides in moving its infrastructure forward in support of manufacturing capacity for the Company's veterinary medication and vaccine lines providing a solid outlook in the medium and long term.

"Skystar has resumed production and distribution of its primary veterinary medicine following GMP recertification by the Ministry of Agriculture. In addition, Skystar's animal and aquaculture vaccine production facility passed initial GMP certification, and, when it operates and reaches its full production levels, is expected to generate at minimum $15 million in annual sales.

"Once operational, the much anticipated vaccine facility will allow Skystar to mass produce vaccines currently produced by hand in large quality controlled batches. Both the certification of the veterinary medicine and vaccine plants are significant milestones for Skystar and are vital in supporting the Company's growth in upcoming years."

Mr. Lu concluded, "In terms of Skystar's performance for the 3rd quarter of 2012, it is noteworthy that, in spite of China's 'soft' economic performance which is partly attributable to fiscal policies designed to control inflation, Skystar has been able to maintain and, at times, marginally increase sales pricing for its products. With this in mind, Skystar's 3rd quarter revenue and bottom line largely reflect a revenue drop in its veterinary medication business in the 3rd quarter, which accounts for nearly 60% of Skystar's revenues in any given period. This is a short term effect related to the closure of Skystar's veterinary medication facility during the pendency of the GMP recertification process. Now that Skystar has resumed production at this facility, Skystar can continue its commitment to maintaining bottom line profitability in its organic business in order to fund growth and expansion initiatives internally for years to come."

Forecast
With the loss of revenue from the veterinary medication plant for all of the third quarter, Skystar's seasonally strongest quarter, the Company is recasting guidance to be in the range of $33 million to $38 million for fiscal 2012.

Financial Summary
Revenues for third quarter 2012, decreased 57% to $8.9 million as compared to $20.9 million in the year ago period.

Gross profit third quarter 2012 was roughly $5.3 million, down 52% from third quarter 2011.

Gross margin for the period was higher at 59% compared to 52% in the year ago period, due to the change in available product mix for sale.

Total operating expenses for third quarter 2012 was $1.6 million, or 18% of total revenue, compared with $1.9 million or 9% of total revenue in the year ago period.

Research and development costs totaled roughly $200,000 for the period, as compared to roughly $91,000 for the three months ended September 30, 2011, an increase of 118%.

Selling expenses totaled $690,000 for third quarter 2012 as compared to $1.2 million for the comparable year ago period this was a decrease of roughly $480,000 or 41%.

General and administrative expenses totaled $730,000 in the third quarter of 2012 as compared to $602,000 for the year ago period, an increase of $128,000 or 21%.

Operating income decreased 59% year over year and was $3.6 million in the third quarter of fiscal 2012 as compared to $9.0 million in the year ago period, operating margin remained level at 41% as compared to 43% from the year ago period.

Net income for the third quarter of 2012 was $2.7 million, or $0.36 per fully diluted share. This compares to net income of $7.7 million or $1.08 per fully diluted share in the same quarter of 2011.

As of September 30, 2012, Skystar had approximately $2.7 million in cash and current assets of $73 million and current liabilities of $20 million.

Conference Call & Webcast Information
The Company will host a conference call on Thursday, November 15, 2012 to discuss the quarter. Skystar's conference call will begin promptly at 7:45 a.m. ET to discuss third quarter financial results and operational performance. Mr. Weibing Lu, Skystar's chairman and chief executive officer, will host the call, which will be webcast live.

Webcast
The webcast will be made available on the investor relations section of the Skystar corporate website at http://www.investorcalendar.com/IC/CEPage.asp?ID=170249.

Phone dial-in
Telephone access to the conference call will be available in North America by dialing +1 (877) 407-8031 or internationally by dialing +1 (201) 689-8031.

An audio replay of the conference call will be available approximately two hours following the conclusion of the call and for the following 30 day period. To access the replay in North America, dial +1 (877) 660-6853 or, when calling internationally, dial +1 (201) 612-7415, using conference ID # 398886. An archived replay of the conference webcast will also be available on investor relations section of the Skystar corporate website at http://www.skystarbio-pharmaceutical.com.

To be added to the Company's email distribution for future news releases, please send your request to [email protected].

About Skystar Bio-Pharmaceutical Company
Skystar is a China-based developer and distributor of veterinary healthcare and medical care products. Skystar has four product lines (veterinary medicines, micro-organisms, vaccines and feed additives) and over 284 products. Skystar has formed strategic sales distribution networks covering 29 provinces throughout China. For additional information, please visit http://www.skystarbio-pharmaceutical.com.



            SKYSTAR BIO-PHARMACEUTICAL COMPANY AND SUBSIDIARIES
    CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME
   FOR THE THREE MONTHS AND NINE MONTHS ENDED SEPTEMBER 30, 2012 AND 2011
                                (Unaudited)

                            For Three Months Ended   For Nine Months Ended
                                September 30,            September 30,
                           ----------------------- ------------------------
                              2012         2011        2012         2011
                           ----------  ----------- -----------  -----------

REVENUE, NET               $8,933,005  $20,903,063 $25,730,190  $37,086,158

COST OF REVENUE             3,670,230   10,057,212  11,060,826   18,185,565
                           ----------  ----------- -----------  -----------

GROSS PROFIT                5,262,775   10,845,851  14,669,364   18,900,593
                           ----------  ----------- -----------  -----------

OPERATING EXPENSES:
Research and development
 costs                        198,838       91,124     533,024    2,180,147
Selling expenses              692,009    1,174,928   2,068,192    2,154,158
General and administrative
 expenses                     730,539      602,248   3,670,254    2,412,339
                           ----------  ----------- -----------  -----------
Total operating expenses    1,621,386    1,868,300   6,271,470    6,746,644
                           ----------  ----------- -----------  -----------

INCOME FROM OPERATIONS      3,641,389    8,977,551   8,397,894   12,153,949
                           ----------  ----------- -----------  -----------

OTHER INCOME (EXPENSE):
Other income (expense),
 net                             (734)       9,421      55,264        5,054
Interest income (expense),
 net                         (199,238)      15,036    (378,779)     (54,265)
Change in fair value of
 warrant/purchase option
 liability                      7,000      171,765      29,400    1,267,412
                           ----------  ----------- -----------  -----------
Total other income
 (expense), net              (192,972)     196,222    (294,115)   1,218,201
                           ----------  ----------- -----------  -----------

INCOME BEFORE PROVISION
 FOR INCOME TAXES           3,448,417    9,173,773   8,103,779   13,372,150

PROVISION FOR INCOME TAXES    717,163    1,446,112   1,768,905    2,205,267
                           ----------  ----------- -----------  -----------

NET INCOME                  2,731,254    7,727,661   6,334,874   11,166,883

OTHER COMPREHENSIVE INCOME
Foreign currency
 translation adjustment      (198,269)     898,786     484,203    2,494,959
                           ----------  ----------- -----------  -----------

COMPREHENSIVE INCOME       $2,532,985  $ 8,626,447 $ 6,819,077  $13,661,842
                           ==========  =========== ===========  ===========

EARNINGS PER SHARE:
Basic                      $     0.36  $      1.08 $      0.85  $      1.56
                           ==========  =========== ===========  ===========
Diluted                    $     0.36  $      1.08 $      0.85  $      1.56
                           ==========  =========== ===========  ===========

WEIGHTED AVERAGE NUMBER OF
 COMMON SHARES:
Basic                       7,604,800    7,172,354   7,426,082    7,171,530
                           ==========  =========== ===========  ===========
Diluted                     7,604,800    7,172,354   7,426,082    7,174,668
                           ==========  =========== ===========  ===========





             SKYSTAR BIO-PHARMACEUTICAL COMPANY AND SUBSIDIARIES
                    CONDENSED CONSOLIDATED BALANCE SHEETS

                                                September 30,  December 31,
                                                    2012           2011
                                                 (Unaudited)
                    ASSETS
CURRENT ASSETS:
  Cash                                         $    2,668,532 $    7,048,968
  Accounts receivable, net of allowance for
   doubtful accounts of $472,483 and $438,678
   as of September 30, 2012 and December 31,
   2011, respectively                              15,457,752      3,391,493
  Inventories                                      15,272,511     14,851,159
  Deposits, prepaid expenses and other
   receivables                                      3,139,404      3,421,487
  Prepayments to suppliers                         34,834,548     29,226,961
  Loans receivable                                  2,106,998        964,088
                                               -------------- --------------
    Total current assets                           73,479,745     58,904,156
                                               -------------- --------------

PROPERTY, PLANT AND EQUIPMENT, NET                 28,904,306     28,376,559

CONSTRUCTION-IN-PROGRESS                            8,686,322      8,839,055

OTHER ASSETS:
  Long-term prepayments                             1,033,875      1,512,817
  Long-term prepayments for acquisitions              177,296        569,788
  Intangible assets, net                            5,406,479      5,674,206
                                               -------------- --------------
    Total other assets                              6,617,650      7,756,811
                                               -------------- --------------
      Total assets                             $  117,688,023 $  103,876,581
                                               ============== ==============

     LIABILITIES AND SHAREHOLDERS' EQUITY

CURRENT LIABILITIES:
  Accounts payable                             $    4,123,218 $    1,047,067
  Other payables and accrued expenses               3,575,584      5,274,598
  Short-term loans                                  9,181,400      7,366,320
  Deposits from customers                           1,347,993      1,432,529
  Taxes payable                                     1,238,105        160,081
  Due to related parties                              386,533         56,273
                                               -------------- --------------
    Total current liabilities                      19,852,833     15,336,868
                                               -------------- --------------

OTHER LIABILITIES:
  Long-term loan                                    1,266,400              -
  Deferred government grant                           395,750        393,500
  Warrant/purchase option liability                    14,000         43,400
                                               -------------- --------------
    Total other liabilities                         1,676,150        436,900
                                               -------------- --------------
      Total liabilities                            21,528,983     15,773,768
                                               -------------- --------------

COMMITMENTS AND CONTINGENCIES

SHAREHOLDERS' EQUITY
  Preferred stock, $0.001 par value,
   50,000,000 shares authorized. No Series "A"
   shares authorized. 48,000,000 Series "B"
   shares authorized. No Series "B" shares
   issued and outstanding                                   -              -
  Common stock, $0.001 par value, 40,000,000
   shares authorized, 7,604,800 and 7,161,919
   shares issued and outstanding as of
   September 30, 2012 (Unaudited) and December
   31, 2011, respectively                               7,605          7,162
  Paid-in capital                                  37,021,085     35,784,378
  Statutory reserves                                5,708,135      5,708,135
  Retained earnings                                44,826,905     38,492,031
  Accumulated other comprehensive income            8,595,310      8,111,107
                                               -------------- --------------
    Total shareholders' equity                     96,159,040     88,102,813
                                               -------------- --------------
      Total liabilities and shareholders'
       equity                                  $  117,688,023 $  103,876,581
                                               ============== ==============



            SKYSTAR BIO-PHARMACEUTICAL COMPANY AND SUBSIDIARIES
              CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
           FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2012 AND 2011
                                (Unaudited)

                                                     Nine months ended
                                                       September 30,
                                                     2012          2011
                                                ------------- -------------
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income                                      $   6,334,874 $  11,166,883
Adjustments to reconcile net income to net cash
 provided by (used in) operating activities:
  Depreciation                                        920,444       709,749
  Amortization                                        300,589       432,098
  Provision for doubtful accounts                      31,340
  Change in fair value of warrant/purchase
   option liability                                   (29,400)   (1,267,412)
  Common stock to be issued to related parties
   for compensation                                                  72,965
  Common stock issued under 2010 stock
   incentive plan                                   1,037,911
Change in operating assets and liabilities
  Accounts receivable                             (12,094,949)   (4,566,868)
  Inventories                                        (336,902)   (6,890,055)
  Deposits, prepaid expenses and other
   receivables                                        404,130       151,534
  Prepayments to suppliers                         (5,426,601)   (8,750,609)
  Accounts payable                                  3,112,002     1,073,204
  Other payables and accrued expenses              (1,361,439)      710,264
  Deposits from customers                             (92,856)      123,582
  Taxes payable                                     1,078,604     4,234,408
                                                ------------- -------------
  Net cash used in operating activities            (6,122,253)   (2,800,257)
                                                ------------- -------------

CASH FLOWS FROM INVESTING ACTIVITIES:
Payments of long-term prepayments                    (343,960)     (357,226)
Refund of long-term prepayments                       475,560
Loans to third parties                             (1,941,248)   (2,885,501)
Collection of loans to third parties                  802,270    11,054,921
Purchases of property, plant and equipment           (157,782)      (58,560)
Purchases of intangible assets                                      (46,496)
Payments on construction-in-progress                 (182,774)   (7,316,494)
                                                ------------- -------------
Net cash (used in) provided by investing
 activities                                        (1,347,934)      390,644
                                                ------------- -------------

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from short-term loans                      4,503,728     3,277,016
Repayment of short-term loans                      (2,726,544)   (3,043,340)
Proceeds from long-term loan                        1,266,400
Repayment of government grants                       (317,040)
Due to related parties                                331,158         4,960
                                                ------------- -------------
Net cash provided by financing activities           3,057,702       238,636
                                                ------------- -------------

EFFECT OF EXCHANGE RATE CHANGES ON CASH                32,049        66,298
                                                ------------- -------------

DECREASE IN CASH                                   (4,380,436)   (2,104,679)

CASH, beginning of period                           7,048,968     5,887,831
                                                ------------- -------------

CASH, end of period                             $   2,668,532 $   3,783,152
                                                ============= =============

SUPPLEMENTAL DISCLOSURE OF CASH FLOW
 INFORMATION:
Cash paid for interest                          $     508,667 $     266,797
                                                ============= =============
Cash paid for income taxes                      $     971,784 $   1,271,193
                                                ============= =============
Non-cash investing and financing activities
Long-term prepayments transferred to
 construction-in-progress                       $     832,230 $   5,497,461
                                                ============= =============
Long-term prepayments transferred to plant and
 equipment                                      $                 4,727,364
                                                ============= =============
Construction-in-progress transferred to
 property, plant and equipment                  $   1,128,662 $
                                                ============= =============
Share issued to settle payables to related
 parties                                        $     199,239 $
                                                ============= =============



   SKYSTAR BIO-PHARMACEUTICAL COMPANY AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY
                       (Unaudited)



                             Common stock
                          ------------------
                                               Paid-in
                            Shares    Amount   capital
                          ---------- ------- -----------
BALANCE, December 31,
 2011                      7,161,919 $ 7,162 $35,784,378

Share issued under 2010
 stock incentive plan        442,881     443   1,236,707
Foreign currency
 translation
Net income
                          ---------- ------- -----------

BALANCE, September 30,
 2012                      7,604,800 $ 7,605 $37,021,085
                          ========== ======= ===========




                             Retained earnings
                         -------------------------


                                                    Accumulated
                                                       other
                          Statutory                comprehensive
                           reserves   Unrestricted     income       Total
                         ----------- ------------- ------------- -----------
BALANCE, December 31,
 2011                    $ 5,708,135 $  38,492,031 $   8,111,107 $88,102,813

Share issued under 2010
 stock incentive plan                                              1,237,150
Foreign currency
 translation                                             484,203     484,203
Net income                               6,334,874                 6,334,874
                         ----------- ------------- ------------- -----------

BALANCE, September 30,
 2012                    $ 5,708,135 $  44,826,905 $   8,595,310 $96,159,040
                         =========== ============= ============= ===========


Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward-looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding the progress of new product development. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the Company's ability to receive timely certification and related government approvals, its ability to increase production at its existing and future facilities, its ability to maintain and meet forecast production and other performance parameters, effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. More information about some of these risks and uncertainties may be found in the reports filed with the Securities and Exchange Commission by the Company. The Company operates in a highly competitive and changing business and regulatory environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. Except as is expressly required by the federal securities laws, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason. Additional risks that could affect our future operating results are more fully described in our U.S. Securities and Exchange Commission filings, including the Company's most recently filed Quarterly Report for the quarter ended September 30, 2012 and other subsequent filings. These filings are available at www.sec.gov.

Contacts:
Grayling Investor Relations
Christopher Chu
(646) 284-9426
Email Contact

Skystar Bio-Pharmaceutical Company
Scott Cramer Director
Director Corporate Development and U.S. Representative
(407) 645-4433

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

@ThingsExpo Stories
SYS-CON Events announced today that Peak 10, Inc., a national IT infrastructure and cloud services provider, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. Peak 10 provides reliable, tailored data center and network services, cloud and managed services. Its solutions are designed to scale and adapt to customers’ changing business needs, enabling them to lower costs, improve performance and focus inter...
You think you know what’s in your data. But do you? Most organizations are now aware of the business intelligence represented by their data. Data science stands to take this to a level you never thought of – literally. The techniques of data science, when used with the capabilities of Big Data technologies, can make connections you had not yet imagined, helping you discover new insights and ask new questions of your data. In his session at @ThingsExpo, Sarbjit Sarkaria, data science team lead ...
So, you bought into the current machine learning craze and went on to collect millions/billions of records from this promising new data source. Now, what do you do with them? Too often, the abundance of data quickly turns into an abundance of problems. How do you extract that "magic essence" from your data without falling into the common pitfalls? In her session at @ThingsExpo, Natalia Ponomareva, Software Engineer at Google, will provide tips on how to be successful in large scale machine lear...
In his session at @ThingsExpo, Chris Klein, CEO and Co-founder of Rachio, will discuss next generation communities that are using IoT to create more sustainable, intelligent communities. One example is Sterling Ranch, a 10,000 home development that – with the help of Siemens – will integrate IoT technology into the community to provide residents with energy and water savings as well as intelligent security. Everything from stop lights to sprinkler systems to building infrastructures will run ef...
Whether your IoT service is connecting cars, homes, appliances, wearable, cameras or other devices, one question hangs in the balance – how do you actually make money from this service? The ability to turn your IoT service into profit requires the ability to create a monetization strategy that is flexible, scalable and working for you in real-time. It must be a transparent, smoothly implemented strategy that all stakeholders – from customers to the board – will be able to understand and comprehe...
Machine Learning helps make complex systems more efficient. By applying advanced Machine Learning techniques such as Cognitive Fingerprinting, wind project operators can utilize these tools to learn from collected data, detect regular patterns, and optimize their own operations. In his session at 18th Cloud Expo, Stuart Gillen, Director of Business Development at SparkCognition, will discuss how research has demonstrated the value of Machine Learning in delivering next generation analytics to im...
There is an ever-growing explosion of new devices that are connected to the Internet using “cloud” solutions. This rapid growth is creating a massive new demand for efficient access to data. And it’s not just about connecting to that data anymore. This new demand is bringing new issues and challenges and it is important for companies to scale for the coming growth. And with that scaling comes the need for greater security, gathering and data analysis, storage, connectivity and, of course, the...
This is not a small hotel event. It is also not a big vendor party where politicians and entertainers are more important than real content. This is Cloud Expo, the world's longest-running conference and exhibition focused on Cloud Computing and all that it entails. If you want serious presentations and valuable insight about Cloud Computing for three straight days, then register now for Cloud Expo.
IoT device adoption is growing at staggering rates, and with it comes opportunity for developers to meet consumer demand for an ever more connected world. Wireless communication is the key part of the encompassing components of any IoT device. Wireless connectivity enhances the device utility at the expense of ease of use and deployment challenges. Since connectivity is fundamental for IoT device development, engineers must understand how to overcome the hurdles inherent in incorporating multipl...
The increasing popularity of the Internet of Things necessitates that our physical and cognitive relationship with wearable technology will change rapidly in the near future. This advent means logging has become a thing of the past. Before, it was on us to track our own data, but now that data is automatically available. What does this mean for mHealth and the "connected" body? In her session at @ThingsExpo, Lisa Calkins, CEO and co-founder of Amadeus Consulting, will discuss the impact of wea...
SYS-CON Events announced today that Stratoscale, the software company developing the next generation data center operating system, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. Stratoscale is revolutionizing the data center with a zero-to-cloud-in-minutes solution. With Stratoscale’s hardware-agnostic, Software Defined Data Center (SDDC) solution to store everything, run anything and scale everywhere...
Angular 2 is a complete re-write of the popular framework AngularJS. Programming in Angular 2 is greatly simplified – now it's a component-based well-performing framework. This immersive one-day workshop at 18th Cloud Expo, led by Yakov Fain, a Java Champion and a co-founder of the IT consultancy Farata Systems and the product company SuranceBay, will provide you with everything you wanted to know about Angular 2.
SYS-CON Events announced today that Men & Mice, the leading global provider of DNS, DHCP and IP address management overlay solutions, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. The Men & Mice Suite overlay solution is already known for its powerful application in heterogeneous operating environments, enabling enterprises to scale without fuss. Building on a solid range of diverse platform support,...
You deployed your app with the Bluemix PaaS and it's gaining some serious traction, so it's time to make some tweaks. Did you design your application in a way that it can scale in the cloud? Were you even thinking about the cloud when you built the app? If not, chances are your app is going to break. Check out this webcast to learn various techniques for designing applications that will scale successfully in Bluemix, for the confidence you need to take your apps to the next level and beyond.
We’ve worked with dozens of early adopters across numerous industries and will debunk common misperceptions, which starts with understanding that many of the connected products we’ll use over the next 5 years are already products, they’re just not yet connected. With an IoT product, time-in-market provides much more essential feedback than ever before. Innovation comes from what you do with the data that the connected product provides in order to enhance the customer experience and optimize busi...
Increasing IoT connectivity is forcing enterprises to find elegant solutions to organize and visualize all incoming data from these connected devices with re-configurable dashboard widgets to effectively allow rapid decision-making for everything from immediate actions in tactical situations to strategic analysis and reporting. In his session at 18th Cloud Expo, Shikhir Singh, Senior Developer Relations Manager at Sencha, will discuss how to create HTML5 dashboards that interact with IoT devic...
Artificial Intelligence has the potential to massively disrupt IoT. In his session at 18th Cloud Expo, AJ Abdallat, CEO of Beyond AI, will discuss what the five main drivers are in Artificial Intelligence that could shape the future of the Internet of Things. AJ Abdallat is CEO of Beyond AI. He has over 20 years of management experience in the fields of artificial intelligence, sensors, instruments, devices and software for telecommunications, life sciences, environmental monitoring, process...
SYS-CON Events announced today that Ericsson has been named “Gold Sponsor” of SYS-CON's @ThingsExpo, which will take place on June 7-9, 2016, at the Javits Center in New York, New York. Ericsson is a world leader in the rapidly changing environment of communications technology – providing equipment, software and services to enable transformation through mobility. Some 40 percent of global mobile traffic runs through networks we have supplied. More than 1 billion subscribers around the world re...
Digital payments using wearable devices such as smart watches, fitness trackers, and payment wristbands are an increasing area of focus for industry participants, and consumer acceptance from early trials and deployments has encouraged some of the biggest names in technology and banking to continue their push to drive growth in this nascent market. Wearable payment systems may utilize near field communication (NFC), radio frequency identification (RFID), or quick response (QR) codes and barcodes...
SYS-CON Events announced today that Fusion, a leading provider of cloud services, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. Fusion, a leading provider of integrated cloud solutions to small, medium and large businesses, is the industry's single source for the cloud. Fusion's advanced, proprietary cloud service platform enables the integration of leading edge solutions in the cloud, including cloud...